Mediator® Phosphatidic Acid
Mechanism of Action +
### Introduction to Phosphatidic Acid Phosphatidic acid (PA) is a diacylglycerol phospholipid consisting of a glycerol backbone, two fatty acid tails, and a phosphate group. While it serves as a fundamental structural intermediate in the biosynthesis of other glycerophospholipids and triacylglycerols, its most critical role in sports nutrition is its function as a potent lipid second messenger. In skeletal muscle, intracellular concentrations of PA dictate the activation state of key anabolic signaling pathways, most notably the mechanistic target of rapamycin (mTOR).
### Endogenous Synthesis and Mechanical Transduction In vivo, PA is generated through several distinct enzymatic pathways. The most prominent pathway during mechanical stress (such as resistance training) involves Phospholipase D (PLD) (EC 3.1.4.4). PLD hydrolyzes the phosphodiester bond of phosphatidylcholine to yield PA and choline. A secondary pathway involves Diacylglycerol kinase (DAGK) (EC 2.7.1.107), which phosphorylates diacylglycerol (DAG) to form PA. When skeletal muscle fibers undergo mechanical tension and eccentric loading, the structural deformation of the sarcolemma and Z-lines triggers a mechanotransduction cascade that rapidly upregulates PLD and DAGK activity. This results in a localized, transient spike in intracellular PA concentrations, which serves as the biochemical signal that mechanical work has been performed and structural adaptation (hypertrophy) is required.
### The mTORC1 Signaling Cascade The primary target of Phosphatidic Acid in skeletal muscle is mTOR Complex 1 (mTORC1), a master regulator of cell growth and protein synthesis. PA physically interacts with mTOR by binding directly to the FKBP12-rapamycin binding (FRB) domain. This lipid-protein interaction allosterically activates the kinase activity of mTORC1. Once activated, mTORC1 phosphorylates several downstream effectors. It phosphorylates ribosomal protein S6 kinase beta-1 (S6K1), which subsequently phosphorylates ribosomal protein S6, promoting the translation of mRNA species that encode ribosomal proteins and elongation factors. Concurrently, mTORC1 phosphorylates eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). In its unphosphorylated state, 4E-BP1 tightly binds and inhibits eIF4E. Upon phosphorylation by mTORC1, 4E-BP1 releases eIF4E, allowing it to assemble with eIF4G and eIF4A to form the active eIF4F complex. This complex binds to the 5' cap of mRNAs, initiating cap-dependent translation and driving global muscle protein synthesis (MPS).
### Exogenous Supplementation and Pharmacokinetics The rationale behind supplementing with Mediator® Phosphatidic Acid is to artificially elevate systemic and intracellular PA levels, thereby lowering the threshold for mTORC1 activation and amplifying the anabolic response to resistance training. Upon oral ingestion, exogenous PA enters the gastrointestinal tract where it is subjected to hydrolysis by pancreatic phospholipase A2 (PLA2) (EC 3.1.1.4), yielding lysophosphatidic acid (LPA) and free fatty acids. These lipid constituents are absorbed by enterocytes in the small intestine and subsequently re-esterified into PA or incorporated into other complex lipids for transport via chylomicrons. While the exact pharmacokinetic profile (Tmax, absolute bioavailability, and half-life) of intact PA reaching skeletal muscle tissue requires further elucidation, clinical outcomes demonstrate that a daily oral dose of 750 mg is sufficient to elicit measurable physiological effects on muscle mass and strength. The exogenous supply is hypothesized to integrate into the sarcolemma and intracellular membranes, providing a larger pool of PA that can interact with mTORC1 when mechanical tension is applied.
### Synergistic Effects with Resistance Training It is critical to note that exogenous PA supplementation is highly synergistic with, and largely dependent upon, mechanical stimulation. While PA can activate mTORC1 independently in vitro, the robust hypertrophic adaptations observed in clinical trials occur when PA is combined with a structured resistance training program. The mechanical tension activates endogenous PLD, while the exogenous PA provides an amplified substrate pool, resulting in a hyper-activation of the mTORC1 pathway that exceeds what training or supplementation could achieve in isolation.
What is Mediator® Phosphatidic Acid? +
How does Phosphatidic Acid work? +
What is the clinically recommended dose? +
When is the best time to take it? +
Do I need to do a loading phase? +
Will I feel it working immediately? +
Does it help with fat loss? +
Is Mediator® better than generic Phosphatidic Acid? +
Can women take Phosphatidic Acid? +
Do I need to cycle it? +
What happens if I take less than 750 mg? +
Can I stack it with Creatine? +
Are there any known side effects? +
Does it work without exercise? +
Is it a steroid or prohormone? +
Everything About Mediator® Phosphatidic Acid Article
## What It Does Mediator® Phosphatidic Acid (PA) is a specialized lipid molecule that plays a critical role in cellular signaling, specifically within skeletal muscle. Unlike traditional macronutrients that merely provide the building blocks for tissue, PA acts as a direct molecular switch. Its primary function is to activate the mechanistic target of rapamycin (mTOR) pathway, which is the body's master regulator of muscle protein synthesis. When you lift weights, your muscle fibers naturally produce a small amount of PA to signal the body to grow and adapt. Supplementing with Mediator® Phosphatidic Acid aims to amplify this signal, effectively telling your body to build more muscle mass and increase strength output in response to your training.
## The Science At a biochemical level, Phosphatidic Acid is a diacylglycerol phospholipid. During mechanical stress (such as the eccentric portion of a heavy lift), an enzyme called Phospholipase D (PLD) is activated, which synthesizes PA within the muscle cell. This newly formed PA binds directly to the FKBP12-rapamycin binding (FRB) domain of mTOR Complex 1 (mTORC1). This binding event allosterically activates mTORC1, triggering a cascade of phosphorylation events involving p70S6K and 4E-BP1. These downstream effectors initiate cap-dependent translation, which is the biochemical process of assembling amino acids into new muscle proteins. By taking exogenous PA, you are increasing the intracellular pool of this vital signaling lipid, thereby lowering the threshold required to trigger a robust anabolic response.
## What The Research Says The clinical evidence for Phosphatidic Acid is primarily focused on resistance-trained men. According to data aggregated by Examine.com: * **Muscle Mass:** There is Grade B (Moderate confidence) evidence across 2 studies showing that 750 mg of PA daily produces a notable magnitude of effect on increasing lean muscle mass. * **Strength:** There is Grade C (Low confidence) evidence across 2 studies showing minor improvements in both Bench Press and Leg Press strength. * **Power Output:** There is Grade C (Low confidence) evidence across 2 studies showing a minor magnitude of effect on overall power output. * **Fat Mass:** Current research (Grade D, Low confidence) indicates that PA does not have a significant effect on reducing body fat.
## Dosing Guide The clinical standard dose for Mediator® Phosphatidic Acid is **750 mg per day**. * **Training Days:** Take the full 750 mg dose approximately 30 to 60 minutes prior to your resistance training session. * **Non-Training Days:** Take 750 mg at any time of the day to maintain elevated systemic levels. * **Loading Phase:** There is no evidence to suggest a loading phase is necessary or beneficial.
## Forms Compared **Mediator® Phosphatidic Acid** is the patented, trademarked form developed by Chemi Nutra. It is the specific raw material that has been utilized in the primary clinical trials demonstrating efficacy for muscle mass and strength. Generic phosphatidic acid exists, but it lacks the clinical validation and standardization guarantees provided by the Mediator® trademark.
## When & How To Take It Timing is an important factor for maximizing the benefits of PA. Because its primary mechanism involves synergizing with the mechanical tension of exercise, taking it 30-60 minutes pre-workout ensures that systemic levels are peaking just as you begin to break down muscle tissue. On rest days, timing is less critical, and it can be taken with any meal.
## Stacking Phosphatidic Acid stacks exceptionally well with other muscle-building compounds. Because PA activates mTOR via a lipid-signaling pathway, it can be combined with Leucine or HMB (which activate mTOR via amino acid sensing pathways) and Creatine Monohydrate (which operates via cellular hydration and ATP regeneration). A high-protein diet is also mandatory, as PA provides the *signal* to build muscle, but dietary amino acids provide the *materials*.
## Who Should Take It Mediator® Phosphatidic Acid is best suited for intermediate to advanced resistance-trained men and women who have already optimized their diet and training regimens. If you have hit a plateau in your muscle mass accumulation or strength gains, PA serves as an advanced, non-hormonal tool to help push past those sticking points.
## Who Should NOT Take It Beginners who have not yet mastered basic training consistency and nutrition will not see a meaningful return on investment from PA. Additionally, because PA is a direct mTOR activator, individuals with a history of conditions where cellular proliferation is a concern should consult a physician before use, though specific contraindications are currently lacking in the sports nutrition literature.
## The Bottom Line Mediator® Phosphatidic Acid is a scientifically validated, non-hormonal muscle builder with moderate evidence supporting its ability to increase lean mass and minor evidence for boosting strength. At the clinical dose of 750 mg per day, it acts as a cellular amplifier for the hard work you put in at the gym. It is not a magic pill, but for dedicated lifters, it offers a distinct biochemical advantage.